Literature DB >> 26418099

Is It Possible to Draw a Risk Map for Obturator Nerve Injury During Pelvic Lymph Node Dissection? The Heilbronn Experience and a Review of the Literature.

Ali Serdar Gözen1, Tevfik Aktoz2, Yigit Akin1, Jan Klein1, Philip Rieker1, Jens Rassweiler1.   

Abstract

OBJECTIVE: Obturator nerve injury (ONI) is a rare complication during pelvic lymph node dissection (PLND), in extraperitoneal laparoscopic radical prostatectomy (e-LRP), and/or extraperitoneal robotic-assisted laparoscopic radical prostatectomy (e-RALP). It is important to recognize ONI during the initial operation, maximizing the feasibility of simultaneous repair. Here we report our experience with ONI during e-LRP/e-RALP procedures and draw an injury risk map.
MATERIALS AND METHODS: Between December 1999 and November 2014, 2531 e-LRPs and 1027 e-RALPs were performed. Five patients (3 during e-LRP, 2 during e-RALP) experienced ONI in the proximal part of the nerve. Obturator nerves were clipped during the 3 e-LRP cases. Clips were immediately removed, and patients received physiotherapy with medical treatments in the postoperative period. During e-RALP, two obturator nerves were transected and subsequently repaired using the robotic Da Vinci(®) Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA). ONI types were investigated in detail in these patients, and current published studies were analyzed in order to draw a risk map.
RESULTS: Mean follow-up was 18.8 ± 2.7 months. In total, 3558 cases (2531 e-LRPs, 1027 e-RALPs) were performed. ONI occurred in 3 e-LRP (0.1%) and 2 e-RALP (0.1%) patients. Simultaneous repair was performed successfully in all cases, as clips were removed in e-LRP cases and obturator nerves were repaired using 6/0 polypropylene (Prolene(®); Ethicon, Somerville, NJ) suture in e-RALP cases. There was no complication associated with obturator nerve functions such as adductor function and/or neurologic deficiency during long-term follow-up. In view of published studies in the literature, the proximal part of the obturator nerve is at highest risk for injury during PLND, representing 77.8% of reported cases of ONI.
CONCLUSIONS: According to our ONI risk map, the proximal part of the obturator nerve is at higher risk for injury during PLND. Careful dissection and a good knowledge of pelvic anatomy are essential for preventing ONI. Successful ONI management can be performed simultaneously in experienced hands.

Entities:  

Mesh:

Year:  2015        PMID: 26418099     DOI: 10.1089/lap.2015.0190

Source DB:  PubMed          Journal:  J Laparoendosc Adv Surg Tech A        ISSN: 1092-6429            Impact factor:   1.878


  5 in total

1.  Robotic resection of an obturator schwannoma with preservation of normal nerve fascicles and function.

Authors:  Hubert Perrin; Philippe Brunner; Jean Claude Ortega; Bertrand Mercier; Nathalie Clement; Christophe Robino; Maurice Chazal
Journal:  J Robot Surg       Date:  2017-03-25

2.  Management of obturator nevre injury during pelvic lymph node dissection.

Authors:  Taha Numan Yıkılmaz; Erdem Öztürk; Nurullah Hamidi; Halil Başar; Önder Yaman
Journal:  Turk J Urol       Date:  2018-05-21

3.  Embarking with laparoscopic radical prostatectomy and dealing with the complications and collateral problems: A single-center experience.

Authors:  Hakan Akdere; Tevfik Aktoz; Mehmet Gürkan Arıkan; İrfan Hüseyin Atakan; Domenico Veneziano; Ali Serdar Gözen
Journal:  Turk J Urol       Date:  2019-10-21

4.  Neuropathic painful complications due to endopelvic nerve lesions after robot-assisted laparoscopic prostatectomy: Three case reports.

Authors:  Marco Cascella; Giuseppe Quarto; Giovanni Grimaldi; Alessandro Izzo; Raffaele Muscariello; Luigi Castaldo; Barbara Di Caprio; Sabrina Bimonte; Paola Del Prete; Arturo Cuomo; Sisto Perdonà
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

Review 5.  A narrative review of pelvic lymph node dissection in prostate cancer.

Authors:  Douglas C Cheung; Neil Fleshner; Shomik Sengupta; Dixon Woon
Journal:  Transl Androl Urol       Date:  2020-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.